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281: H1122–H1130, 2001.—There is growing evidence that
hypertriglyceridemia exacerbates ischemic injury. We tested
the hypothesis that triglycerides impair myocardial recovery
from low-flow ischemia in an ex vivo model and that such an
effect is related to endothelin-1. Hyperglycemic (glucose con-
centration 5 12 mmol/l) and hyperinsulinemic (insulin con-
centration 5 1.2 mmol/l) isolated rat hearts were perfused
with Krebs-Henseleit buffer (PO2 5 670 mmHg, pH 7.4, 37°C)
added with increasing triglycerides (0, 1,000, 2,000, and
4,000 mg/dl, n 5 6–9 rats/group). Hearts were exposed to 60
min of low-flow ischemia (10% of basal coronary flow), fol-
lowed by 30 min of reperfusion. We found that increasing
triglycerides impaired both the diastolic (P , 0.005) and
systolic (P , 0.02) recovery. The release of endothelin-1
during reperfusion increased linearly with triglyceride con-
centration (P 5 0.0009). Elevated triglycerides also increased
the release of nitrite and nitrate (NOx), the end products of
nitric oxide, up to 6 mmol/min. Trimetazidine (1 mmol) fur-
ther increased NOx release, blunted endothelin-1 release,
and protected myocardial function during recovery. We con-
clude that high triglyceride levels impair myocardial recov-
ery after low-flow ischemia in association with endothelin-1
release. The endothelium-mediated effect of triglycerides on
both contractile recovery and endothelin-1 release is pre-
vented by 1 mM trimetazidine.
nitric oxide
ACCUMULATING EPIDEMIOLOGICAL EVIDENCE suggests that
the situation characterized by elevated plasma triglyc-
erides (TG) is associated with increased cardiovascular
risk independent of factors such as hyperglycemia and
elevated plasma cholesterol (3). Hypertriglyceridemia
is also a critical risk factor for coronary heart disease
(CHD) mortality in subjects with impaired glucose tol-
erance or diabetes (18). Furthermore, hypertriglyceri-
demia is a common finding in survivors of acute myo-
cardial infarction (27). This epidemiological evidence
suggests that TG influence myocardial performance
after ischemia-reperfusion independently of athero-
sclerosis progression.
Although its role in acute ischemia-reperfusion is
controversial, endothelin-1 (ET-1) is known to exacer-
bate injury, likely via activation of ET type A receptors
(9). Studies in isolated hearts showed that ET-1 release
increases on early reperfusion after ischemia, thereby
contributing to injury (7), and that ET-1 is a major
factor that depresses cardiac function (6) and causes
cell necrosis (8). These findings are consistent with
other studies (21, 23, 30) demonstrating a relationship
between ET-1 and the pathogenesis of myocardial is-
chemia. In humans, acute hypertriglyceridemia stim-
ulates ET-1 release in normal subjects (36). In addi-
tion, hypertriglyceridemia is related with elevated
plasma levels of ET-1 in glucose-intolerant and type II
diabetic patients with insulin resistance syndrome
(37). However, on an experimental ground, a link
among hypertriglyceridemia, ET-1, and the outcome of
the ischemia-reperfusion injury is still lacking. The
purpose of this study is to provide experimental evi-
dence of that link by testing the hypothesis that TG
exacerbate the injury driven by ischemia-reperfusion
and that this phenomenon is linked to ET-1.
The isolated crystalloid-perfused heart may be a
suitable model to test this issue in three steps: 1)
evaluate the direct acute effect of high TG on postis-
chemic recovery, 2) assess the link between the reper-
fusion injury and ET-1 release, and 3) evaluate the
protection afforded by the piperazine drug trimetazi-
dine (TMZ). No attempt is made to investigate the
mechanism underlying ET-1 recognition by cardiac
myocytes, because it is known to involve ET type A
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receptors (9, 10, 19, 43). However, by testing the effect
of TMZ, a recognized anti-anginal and anti-ischemic
agent (13), one may understand the site of action of TG.
Indeed, TMZ inhibits the activity of 3-ketoacyl coen-
zyme A (CoA) thiolase, the key enzyme of fatty acid
b-oxidation, thereby increasing myocardial oxidative
glucose metabolism (29), and the inability to utilize
glucose for the oxidative metabolism increases cardio-
vascular risk in the presence of excess fatty acids (34).
Citrate release is a useful index of the flux through the
b-oxidation path (50). In addition, because inactivation
of nitric oxide (NO) may play a prominent role in
cardiovascular disease (15), we measured the release of
nitrite and nitrate (NOx), the end products of NO
metabolism, during the reperfusion as a probe to as-
sess the viability of the endothelial cells.
To mimic the metabolic situation occurring in type II
diabetic patients during the postprandial period, we
selected hyperglycemic and hyperinsulinemic condi-
tions. Indeed, hyperinsulinemia increases plasma ET-1
in humans (36) because insulin stimulates ET-1 secre-
tion from human endothelial (17) and vascular smooth
muscle cells (2). In this study, hearts perfused in the
presence of increasing TG concentration ([TG]), as well
as 1026 M TMZ, are exposed to low-flow ischemia and
reperfused. Data will show that the postischemic in-
jury is proportional to [TG] and ET-1 release and that
the deleterious effects of elevated TG are prevented by
TMZ.
MATERIALS AND METHODS
Heart perfusion. Male Sprague-Dawley rats (250–280 g
body wt) fed ad libitum were anesthetized with heparinized
thiopental sodium (10 mg/100 g body wt). Hearts were ex-
cised, immersed in isotonic saline solution (20°C) and
mounted on the perfusion system as described previously
(44). The time required for these operations never exceeded
45 s and was typically in the 15- to 30-s range. Langendorff
perfusion started immediately with the media described be-
low. A peristaltic pump (Gilson; Viliers Le Bel, France) de-
livered the medium at desired flows to the 8-mm-pore-size
filter (47-mm diameter, Nucleopore; Pleasanton, CA), the
preheater, and the aortic cannula. All the components of the
apparatus, including the heart chamber, the oxygenator, and
the preheater, were connected to a 1,760-W external water
bath (Endocal, Neslab Instruments; Newington, NH) kept at
37.5 6 0.5°C. A latex balloon in the left ventricle was con-
nected to a pressure transducer (model 52-9966, Harvard
Apparatus; Natick, MA) to monitor myocardial performance
(see Experimental protocol). An additional transducer con-
nected to the aortic cannula provided the coronary perfusion
pressure (CPP). A cannula was inserted into the pulmonary
artery to collect the venous return and to monitor venous PO2
by an O2-sensing electrode (model 5300 Oxygen Monitor,
Yellow Springs Instruments; Yellow Springs, OH). The in-
vestigation conforms to the guidelines in the Guide for the
Care and Use of Laboratory Animals (National Institutes of
Health, Publication No. 85-23, Revised 1985).
The perfusion media consisted of a Krebs-Henseleit buffer
with 2.0 mmol/l free Ca21, 12 mmol/l glucose, and 20 mU/l
human recombinant insulin (Actrapid HM, Novo Nordisk;
Rome, Italy) added with variable amounts (22.5–90 ml/l
perfusion medium) of Intralipid 20% (Fresenius Kabi; Ve-
rona, Italy). The medium composition was not changed dur-
ing the protocol. Before dilution, Intralipid 20% contained
200 g/l TG, 12 g/l phospholipids, 25 g/l glycerol, and 257–280
mg/l cholesterol. Linoleic acid is the main fatty acid in TG (18
carbons, 2 cis double bonds), with linolenic, oleic, palmitic,
and stearic acids accounting for ,50% of the total. Vitamin E
present in the mixture partly inhibits oxidation of unsatur-
ated double bonds (G. Arcuri and F. Kabi, unpublished com-
munication).
In control hearts (TG0 group, n 5 9), no Intralipid was
added to the Krebs-Henseleit buffer. In the TG1,000 (n 5 9),
TG2,000 (n 5 7), and TG4,000 (n 5 6) groups, Intralipid was
added to the medium to yield [TG] ;1,000, 2,000, and 4,000
mg/dl. The TG4,000 1 TMZ (n 5 5) group was similar to
TG4,000 group, but with 1026 M freshly prepared TMZ (Ser-
vier Laboratories; Courbevoie, France). The medium was
equilibrated at PO2 5 670 6 6 mmHg (means 6 SE) and
PCO2 5 36 6 1 mmHg in membrane oxygenators (45). The
resulting pH was 7.38 6 0.01 at 37°C.
Myocardial performance was monitored by a LabView sys-
tem (National Instruments, Austin, TX) running on Macin-
tosh Quadra 700 (Apple; Cupertino, CA). Measurements in-
cluded the heart rate (HR), the end-diastolic pressure (EDP),
the peak systolic pressure (PSP), the maximal rates of pres-
sure development (1dP/dtmax) and relaxation (2dP/dtmax),
and the coronary perfusion pressure (CPP). From these pa-
rameters, we derived the left ventricular developed pressure
(LVDP 5 PSP 2 EDP) and LVDP zHR, which represents the
myocardial contractile work. The resistance was calculated
as (CPP 2 EDP)/(flow rate)/(ventricle weight) (11). The O2
uptake was calculated from the arteriovenous PO2 difference
and flow rate.
Experimental protocol. All hearts were stabilized for 20
min at a flow rate of 15 ml/min for baseline measurements.
During this period, the volume of the intraventricular bal-
loon was adjusted to yield an EDP of 10 6 1 mmHg and was
kept constant afterward. Hearts were then subjected to low-
flow ischemia for 60 min by reducing the flow to 1.5 ml/min.
After ischemia, hearts were reperfused for 30 min with the
same flow rate used during baseline. The recovery of postis-
chemic myocardial performance was evaluated at the end of
the reperfusion either as an increase of EDP and CPP above
baseline values (DEDP and DCPP, respectively) or as a per-
centage of HR, LVDP, 1dP/dtmax, 2dP/dtmax, and LVDP zHR.
Measurements in the coronary effluent. Glucose was mea-
sured by a glucose-oxidase analyzer (Yellow Springs Instru-
ments). Insulin was measured in a single assay [within-assay
coefficient of variance (CV)-3.0%, between-assay CV-5.0%]
with a microparticle enzyme immunoassay (sensitivity 5 6
pmol/l, cross-reactivity with proinsulin ,2%; IMX, Abbott
Laboratories; Abbott Park, IL). Free fatty acid, TG, citrate,
and lactate were measured by automated enzymatic spec-
trofluorimetric methods adapted to COBAS FARA II (within-
assay CV-3.0%, between-assay CV-3.0%; Hoffman-La Roche;
Basel, Switzerland).
To measure ET-1, the coronary effluent was collected every
10 min for 30 min during the reperfusion, and the samples
were extracted on SepPack C18 minicolumn (Amprep, Am-
ersham International; Buckinghamshire, UK). The eluate
was evaporated in a Speed Vac (model SC110, Savant Instru-
ments; Farmingdale, NY). Samples were then reconstituted
with 250 ml radioimmunoassay buffer and assayed by a
radioimmunoassay kit (Endothelin-1,2 High-sensitivity As-
say System; Amersham International). The antiserum was a
rabbit anti-ET-1 antibody, and the tracer was 125I-labeled
ET-1. The assay sensitivity was 1.25 pg/ml, with a typical
within- and between-assay CV 5 3.0% and 11.9%, respec-
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tively. The total release of ET-1 during the reperfusion was
calculated by taking the area under the curves representing
ET-1 versus time by the trapezoidal rule and by considering,
as a basal value, the ET-1 level measured at the end of
ischemia.
NOx was measured by enzymatic catalysis coupled with
the Griess reaction (49). As for ET-1, total NOx release
during reperfusion was calculated by measuring the area
under the curves representing NOx versus time by the trap-
ezoidal rule, after taking the NOx level measured at the end
of ischemia as the basal value.
Statistics. Data are expressed as means 6 SE. To assess
the effect of increasing [TG], we performed a two-way facto-
rial analysis of variance test (StatView, Abacus Concepts;
Berkeley, CA). To assess the effects of TMZ at constant [TG],
we used Student’s t-test. Simple regression analysis was
performed using the indices of myocardial performance at
recovery as the dependent variables and TG or ET-1 levels as
the independent variables.
RESULTS
The concentration of glucose and insulin in the me-
dia were 12.5 6 0.5 mmol/l and 1.22 6 0.03 mmol/l,
respectively. The level of free fatty acids was ,0.2
mmol/l in both the arterial inflow and venous effluent.
Because all hearts kept contracting through the ische-
mia-reperfusion protocol, all data were available for
analysis. Table 1 shows myocardial performance dur-
ing baseline. All parameters (except for CPP) were not
altered by the increase of TG. Although increased in
the TG1,000 group, resistance was not further altered
for fourfold Intralipid increases. There was no effect of
TMZ during baseline except for the higher O2 uptake in
the TG4,000 1 TMZ group, which reflects the slightly
improved, albeit nonsignificant, performance in TMZ
hearts. Despite some intergroup differences in the O2
uptake-to-LVDP zHR ratio, which helps to address the
relative contribution of carbohydrates and lipids to
energy production, there is no [TG]-associated trend or
significant effects of TMZ.
Fig. 1. Increase of the end-diastolic pressure (A) and of the coronary
perfusion pressures (B) over baseline as measured at the end of
reperfusion. Left P values indicate the significance of the trend as a
function of increasing triglycerides (one-way factorial analysis of
variance test applied to the linear regression). Right P values indi-
cate the significance of the effect of 1026 M trimetazidine (TMZ)
compared with the value corresponding to triglyceride concentration
([triglycerides]) 5 4,000 mg/dl. Data are means 6 SE. NS, not
significant.
Table 1. Myocardial performance during baseline






(n 5 6) P TG4,0001TMZ P
Triglycerides, mg/dl 261 952669 2,0836177 3,8826150 NA* 3,809676 NS†
HR, beats/min 253610 25867 252615 24569 NS* 24469 NS†
Developed pressure, mmHg 11567 9368 124612 138616 NS* 16467 NS†
LVDP zHR, mmHg z1,000 zmin21 28.861.6 23.661.9 31.363.4 33.663.8 NS* 40.162.0 NS†
End-diastolic pressure, mmHg 9.960.2 9.160.4 10.360.4 11.860.7 NS* 10.460.6 NS†
Perfusion pressure, mmHg 8269 120611 121612 113611 0.05* 96616 NS†
Resistance, mmHg zml21 zmin zg 4.7960.57 7.3960.71 7.3760.79 6.7660.75 NS* 5.7561.07 NS†
1dP/dtmax, mmHg/s 3,2016151 2,5426196 3,4966434 3,4876287 NS* 3,9126160 NS†
2dP/dtmax, mmHg/s 2,1106148 1,8426180 2,2636239 2,2176223 NS* 2,7146137 NS†
Venous [lactate], mmol/l 0.1260.04 0.1660.07 0.2160.08 0.1760.02 NS* 0.2160.03 NS†
Venous PO2, mmHg 205632 208636 193643 259624 NS* 163611 0.01†
O2 uptake, mmol/min 9.860.7 9.760.8 10.060.9 8.660.5 NS* 10.660.2 0.01†
O2 uptake/LVDP zHR, mmol zmmHg21 z1,000 0.3460.02 0.4260.03 0.3460.03 0.2760.02 NS* 0.3160.01 NS†
Values are means 6 SE; n, no. of rats. TG, triglycerides; TMZ, trimetazidine; LVDP zHR, left ventricular developed pressure 3 (HR);
1dP/dtmax, maximal rate of pressure development; 2dP/dtmax, maximal rate of pressure relaxation; NA, not applicable; NS, not significant.
Myocardial performance was assessed during baseline perfusion with Krebs-Henseleit medium (2 mmol/l free Ca21, 12 mmol/l glucose, 20
mU/l insulin, and variable amounts of TG). In control hearts (TG0 group), no TG was added. In the TG1,000, TG2,000, TG4,000 groups, Intralipid
was added to the medium to yield a TG concentration of ; 1,000, 2,000, and 4,000 mg/dl, respectively. In the TG4,000 group, 1026 M of freshly
prepared TMZ was added (TG4,000 1 TMZ group). Media were equilibrated at PO2 5 670 6 6 mmHg and PCO2 5 36 6 1 mmHg; resulting
pH was 7.38 6 0.01 at 37°C. Flow was 15 ml/min. *P . 0.05, analysis of variance test vs. TG; †P . 0.05, Student’s t-test vs. TG4,000 group.
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The exposure of hearts to 60-min low-flow ischemia,
followed by 30-min reperfusion, impaired myocardial
performance. Increasing [TG] further impaired recov-
ery. DEDP increased with increasing [TG] (P 5 0.005)
up to 38.5 6 10.7 mmHg (Fig. 1A). DCPP tended to
increase, although nonsignificantly (P 5 0.08). The
presence of 1026 M TMZ in the medium blunted (P 5
0.05) the increase in EDP; DCPP tended to decrease,
although nonsignificantly (P 5 0.07) (Fig. 1B). Figure 2
shows other parameters of the ventricular function.
HR was not affected by TG, but TMZ increased HR at
the end of the postischemic recovery (P 5 0.03). The
recovery of LVDP was progressively impaired by the
increase of [TG] to 55 6 5% of baseline (P 5 0.0008).
However, 1026 M TMZ significantly (P 5 0.02) pro-
tected hearts and increased the recovery of developed
pressure to 81 6 7% baseline. The same trend as that
described for LVDP was also observed for 1dP/dtmax,
2dP/dtmax, and LVDP zHR.
Figure 3, A and B, shows that increasing [TG]
augments ET-1 release during reperfusion from
0.9 6 0.2 ng/min in the absence of TG to 6.3 6 1.6
ng/min in the presence of 4,000 mg/dl TG (P 5 0.001).
The presence of 1026 M TMZ completely blunted the
release of ET-1 (P 5 0.008). Figure 3, C and D, shows
that increasing [TG] slightly increased the release of
NOx. The release of NOx appeared to be blunted
when [TG] 5 2,000 mg/dl because a further [TG]
increase did not augment NOx release. However, in
the presence of 1026 M TMZ, the release of NOx was
augmented threefold with respect to the same [TG]
in the absence of TMZ. Figure 3E shows that the
release of citrate increases linearly with [TG] and is
blunted in the presence of 1026 M TMZ.
Fig. 2. Recovery of heart rate (HR) (A), left ventricular
developed pressure (LVDP) (B), maximal rates of pres-
sure development (C) and relaxation (D), and cross-
product LVDP zHR (E), expressed as percentage of the
baseline value. Data are means 6 SE (see Fig. 1).
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Figure 4, A and B, shows the correlation existing
between ET-1 release and EDP or the recovery of
LVDP zHR measured at the end of the reperfusion. The
correlation is statistically significant (P 5 0.0002 and
P 5 0.01, respectively). Similarly, a significant corre-
lation is found when substituting EDP or LVDP zHR
with either LVDP (P 5 0.002), 1dP/dtmax (P 5 0.005),
or 2dP/dtmax (P 5 0.004) but not CPP (P 5 not signif-
icant).
Figure 5 shows the changes in the O2 uptake-to-
LVDP zHR ratio in the various groups. Low-flow ische-
mia significantly decreased that ratio in all groups
with respect to baseline (P , 0.007). On reperfusion,
the O2 uptake-to-LVDP zHR ratio recovered to near-
normal values, with the exception of the TG4,000 group,
for which that ratio increased from 0.27 6 0.02 to
0.55 6 0.05 mmol zmmHg21 z1,000 (P 5 0.003). Venous
lactate concentration ([lactate]) at the end of ischemia
ranged from 1.6 to 2.3 mmol/l in all groups without
differences among the groups.
DISCUSSION
In this hyperglycemic, hyperinsulinemic model, ele-
vated [TG] in the medium progressively impairs the
postischemic recovery of both systolic and diastolic
functions. The impairment is associated with increased
ET-1 release. The addition of 1026 M TMZ protects
hearts from the deleterious effect of high TG. The
protection is associated with blunted ET-1 release and
increased NOx release.
Critique of the model. By reducing to a reasonable
minimum the number of the involved variables, the
isolated crystalloid-perfused heart model appears suit-
able for studying the effects of TG in the ischemic-
reperfused cardiac muscle. The animals were not pre-
treated; thus the observations relate to acute metabolic
effects. Any interference by neurohormonal factors is
excluded because isolated hearts are denervated. Per-
fusion with blood cell-free media excludes the disturb-
ing effect of neutrophil accumulation and thrombin-
induced platelet aggregation. Temperature is strictly
controlled (60.5°C). A constant balloon volume rules
out differences in loading conditions. The duration and
severity of ischemia are the same in all groups. The
changes in vascular resistance are monitored as DCPP
because the flows were the same in all the groups.
Although the selected experimental conditions with
relatively short ischemia-reperfusion times do not al-
low for appreciable no reflow, the slight, nonsignificant
increase of vascular resistance shown in Fig. 1 indicate
that this phenomenon might have occurred on a longer
time basis. The changes in diastolic contracture are
reflected by DEDP because the balloon volume is fixed
at the start of the experiment and kept constant after-
ward.
Hearts were perfused with media containing glucose
and lipids as oxidizable substrates. The experiments
reported here were not designed to address the ques-
tion of their relative contribution to energy production,
but the changes in the O2 uptake-to-LVDP zHR ratio
reflect different substrate contribution to the rate of
ATP synthesis. The fall of that ratio at the end of
low-flow ischemia is a consequence of increased sub-
strate-level phosphorylation, as it is evident from the
increased venous [lactate]. It is well known that ATP
generated from glycolysis represents a substantial por-
tion of total energy production under low-flow ischemia
(5, 16); this feature was also verified in the same
experimental model as that used in this study (45).
However, the O2 uptake-to-LVDP zHR ratio returned to
near-normal values at the end of reperfusion except for
the TG4,000 group. Thus these hearts shifted from car-
bohydrate to lipid metabolism, a well-known O2 waste
effect (32), to a greater extent than those in the other
groups. Interestingly, in the TG4,000 1 TMZ group, the
ratio was normal, supporting the role of TMZ in shift-
Fig. 3. Releases of endothelin-1 (ET-1) (A), nitrite and nitrate (B),
and citrate (C) during reperfusion. Data are means 6 SE (see Fig. 1).
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ing heart metabolism toward the use of glucose rather
than lipids (29).
TG-associated injury. The deleterious effect of
plasma free fatty acids on myocardial postischemic
injury in vivo is well known (34). However, the level of
free fatty acids in the perfusion media employed in this
study was always ,0.2 mmol/l. Because of the rela-
tively high flow, free fatty acids were undetectable in
the venous effluent. However, it is likely that TG were
in part hydrolyzed in the vascular compartment, with
release of fatty acids into the cytoplasm. Measurement
of the citrate release rate provided evidence of this
mechanism because this rate reflects the mitochon-
drial efflux of citrate and is an index of the concentra-
tion of substrates feeding acetyl-CoA and oxaloacetate
for the citrate synthase reaction (50). The essentially
linear relationship between the citrate release rate and
[TG] supports the view that TG are partly hydrolyzed
into fatty acids, and fatty acids are uptaken into the
myocytes. Intracellular fatty acids are known to de-
press myocardial recovery from ischemia (28), possibly
through increased b-oxidation and decreased glycolysis
and/or glucose oxidation. Measurement of citrate re-
lease during reperfusion rules out the potentially
masking effects of intracellular citrate concentration
peaks that might have occurred during ischemia (24).
The blunted citrate release in TMZ-perfused hearts
reinforces the hypothesis that the protection afforded
by TMZ is exerted through inhibition of b-oxidation
and stimulation of glycolysis and/or glucose oxidation
(29). Glycolysis is important in restoring postischemic
Ca21 homeostasis and myocardial function (26), as well
as in maintaining membrane integrity (5). This study,
however, shows that high TG may impair the postis-
chemic recovery also through increased release of
ET-1. Although this hypothesis requires more mecha-
nistic information on how high TG increases ET-1
formation or expression, the present data demon-
strates that in this model progressively increased [TG]
results in a dose-dependent increase in ET-1 release
and that increased ET-1 is highly related to the ische-
mia-induced performance dysfunction (Fig. 4).
Intralipid is a pool of different types of triglycerides,
with fatty acids with variable chain lengths and num-
bers of cis double bonds. Thus the mechanism of action
of TG in the isolated perfused heart requires further
work to be elucidated. Previous work (48) pointed out
that Intralipid administration during reperfusion is
protective, with linoleic acid and phospholipids having
complementary actions. However, this situation is dif-
ferent from that in the present study, with Intralipid
administered throughout the ischemia-reperfusion
Fig. 4. Correlation between ET-1 release and end-dia-
stolic pressure (A) or the recovery of LVDP zHR (B) at
the end of reperfusion. P 5 0.0002 and 0.01, respec-
tively.
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protocol. Regardless of the involved mechanism, it was
already demonstrated (42) that under normal condi-
tions, the contribution of phospholipids, cholesterol
esters, monoacyl glycerols, and diacyl glycerols to myo-
cardial oxidative metabolism in the presence of TG is
,5% of the total. Although this work deals with ische-
mia-reperfusion and not normal conditions, we believe
that the effects observed here are to be attributed
mainly to TG.
NO. Decreased NO availability plays a significant
role in the reperfusion injury even in the absence of
blood components, especially at the level of the dia-
stolic function (35). Indeed, supplementation with so-
dium nitroprusside during hypoxia improves left ven-
tricle relaxation (14) and NO donors inhibit
reoxygenation-induced hypercontracture (46). The
present data shows that TG increases NOx release,
probably by a mechanism analogous to that described
in small rabbit arteries, by which NO-mediated, shear-
induced dilatation opposes the vasoconstriction elicited
by increased pressure (38). Indeed, ischemia and reper-
fusion cause injury to the vascular endothelium, ex-
pressed as a reduction in NO release (47). However, it
appears from the data shown Fig. 3 that the increase in
NOx is blunted at [TG] 5 2,000 mg/dl, thereby reducing
the possible cardioprotective effect of NO, which is
restored by 1026 M TMZ. It was shown (31) that at low
doses NO may exert a positive inotropic effect on car-
diac function, whereas a relaxation-hastening effect of
NO becomes apparent while the dose of NO is in-
creased. Therefore, it remains to be established
whether the NOx release found in the presence of TMZ
falls within the protective NO dose range. If we assume
that the release of NOx was constant over time during
the 30 min of reperfusion, then the value of 1,200
mmol/l divided by 30 min yields 40 mmol z l21 zmin21
release, which is apparently beneficial to protect hearts
after 60-min low-flow ischemia.
TMZ. We explored the effect of TMZ at concentra-
tions (1026 M) that were previously found efficient with
regard to ischemic protection (4). This concentration is
within the therapeutic range because it compares with
the blood levels obtained in ischemic patients receiving
oral treatment (40). In this study, 1026 M TMZ inhibits
ET-1 secretion, increases the release of NOx, and re-
duces the deleterious effect of high TG.
Several hypotheses, not necessarily exclusive, have
been proposed to explain the effect of TMZ. First, by
inhibiting the activity of 3-ketoacyl CoA thiolase and
the flow through the b-oxidation, TMZ increases oxi-
dative glucose metabolism (29) (see TG-associated in-
jury). Second, by sparing energy during ischemia, TMZ
preserves the ATP pool (1). Third, TMZ reduces the
intracellular acidosis caused by ischemia (39). Fourth,
TMZ enhances mitochondrial function (12). Other
studies aimed at assessing the effect of TMZ on Na1-
K1-ATPase (25) and on mitochondrial Ca21 uptake
(22) showed that this effect occurs only for TMZ levels
much higher than those that protect the myocardium.
In the present study, it is difficult to assess whether
blunted ET-1 release is a consequence of the TMZ
protective effect on myocardium or if TMZ inhibits
ET-1 release by protecting the endothelium. However,
the observation that TMZ greatly increases NOx re-
lease strongly supports the hypothesis that in this
model part of the protection is exerted at the level of
Fig. 5. Oxygen uptake-to-LVDP zHR ratio during the
experimental protocol in the groups. That ratio is ex-
pressed relative to baseline value to emphasize inter-
group variations. #P 5 0.003, significant difference
with respect to baseline (paired Student’s t-test). TG0,
no triglycerides added; TG1,000, TG2,000, and TG4,000,
triglycerides added to medium to concentrations of
1,000, 2,000, and 4,000 mg/dl; TG4,000 1 TMZ, TG4,000 1
1026 M TMZ.
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the endothelial cells. Indeed, immunocytochemical
studies aimed at localizing NO synthase and ET-1 in
the coronary vascular bed showed that both occur in
the endothelial cells (41). Furthermore, pressure-in-
duced tone is regulated by NO and ET-1 but no inter-
action between the two factors was evident because
they involve different kinds of receptors, i.e., a1- and
a2-adrenoceptors (33).
Study limitation and clinical implications. Although
we designed this study to mimic the reduction of coro-
nary blood flow that might occur in atherosclerotic
coronary vessels of hyperglycemic, hyperinsulinemic,
and hyperlipidemic type II diabetic patients during the
postprandial period, extrapolation of our data to the
clinical situation is to be made with care. First, re-
sponses may be different in normal hearts and hearts
from diabetic or hyperlipidemic rats. Second, although
uncommon, the situation of [TG] 5 4,000 mg/dl may be
found in diabetic hyperlipidemic patients in the post-
prandial period. This situation is worth studying be-
cause the link between hypertriglyceridemia and CHD
is best seen in the postprandial period, when patients
experience exaggerated lipemia, probably related to
the delayed clearance of dietary fats (51). The plasma
TG level in the postprandial period is positively corre-
lated (3–4 times) with the fasting TG level (20). Fur-
thermore, normalization of plasma TG is markedly
delayed in CHD patients because of the presence of
gut-derived plasma lipids.
The use of media with increasing Intralipid contents
might in principle alter the vascular tone. However,
although resistance increased from TG0 to TG1,000, it
remained constant up to TG4,000, suggesting that in-
creased viscosity would not have significantly altered
data. Although we cannot rule out the possibility that
the presence of TG induces vasodilation, possibly via
increased NO production, viscosity may not be a cen-
tral problem. Indeed, the mean globule size for In-
tralipid is 340 nm (G. Arcuri and F. Kabi, unpublished
communication), thus in the same order of magnitude
of the size of chilomicrons (75–1,000 nm). However, the
selected way to report data and evaluate statistics, i.e.,
by considering [TG] as a continuous variable, takes
this issue into account.
In this study, we did not investigate whether the
presence of ET-1 receptor antagonists in the perfusion
medium is able to reverse the deleterious effects of
high TG on postischemic myocardial function. This
important issue clearly deserves further work.
In conclusion, high TG progressively impairs the
myocardial recovery from low-flow ischemia. The im-
pairment is significantly related to the release of ET-1,
which appears to mediate the mechanism leading to
injury. TG also increases the release of NO but not
sufficiently to protect the heart from reperfusion in-
jury. By further increasing NO release, 1 mmol/l TMZ
prevents ET-1 release and reverses the harmful myo-
cardial effect of TG. By providing experimental evi-
dence of a link among elevated TG, ET-1, and myocar-
dial ischemia-reperfusion injury, this study supports
the epidemiological evidence that suggests that the
situation characterized by elevated plasma TG is asso-
ciated with increased cardiovascular risk independent
of factors such as hyperglycemia and elevated plasma
cholesterol.
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